Equity Profile

CRL

Charles River Laboratories International, Inc.

Health CareLife Sciences Tools & Services$11.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the Health Care sector, focusing on life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well CRL is managing its costs and generating income.

Expected to be around $2.06.

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand its market share and support future investments.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the Health Care sector, focusing on life sciences tools and services. The company plays a crucial role in supporting the pharmaceutical and biotechnology industries by providing essential research services and products, which are increasingly important as these sectors continue to innovate and expand.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In Q1-2026, CRL reported an EPS of $2.06, surpassing expectations by 5.21%. However, the stock experienced a slight decline of 0.03% the following day, indicating some market skepticism despite the earnings beat.

Management Promises & Guidance

Management emphasized a commitment to maintaining strong operational efficiency.
They indicated ongoing investments in research and development to drive future growth.
Management also highlighted the importance of expanding their service offerings in the biotech sector.

Expectations

Wall Street Expectations

Overall, analysts expect CRL to continue its trend of beating earnings estimates, given its historical performance. However, the lack of specific revenue guidance raises some concerns about future growth prospects.

Bull Case

If CRL can demonstrate strong revenue growth and maintain or improve its margins, it could lead to significant stock appreciation, especially given its history of beating EPS estimates.

Bear Case

On the other hand, if the company fails to provide clear guidance or if operational challenges arise, it could lead to a negative market reaction, particularly given the recent stock performance trends.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.06.

EPS is a key indicator of profitability and will show how well CRL is managing its costs and generating income.

Revenue Growth

Not available.

Revenue growth is vital for assessing the company's ability to expand its market share and support future investments.

Operating Margin

Not available.

Operating margin will help investors understand how efficiently CRL is operating relative to its revenue.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can CRL provide for its life sciences services?

Given the importance of revenue growth in the current market environment, clear figures will help investors gauge the company's future trajectory.

How is CRL managing its operational costs amidst rising inflation?

Understanding cost management strategies will be crucial for assessing the company's profitability and operational efficiency moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CRL's ability to leverage its recent investments in R&D, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

CRL has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.

Recent trends in the biotech sector show increased demand for CRL's services, which could drive revenue higher.

Key Risk

If CRL's revenue growth comes in below 5%, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around CRL's ability to sustain growth in a competitive market while managing costs effectively.

Bull Confirmed If

Demonstrating revenue growth of at least 10% year-over-year would confirm a strong bull case.

Bear Confirmed If

If revenue growth is flat or negative, it would raise significant concerns about CRL's market position.

Pre-Earnings Positioning

Options Market

Implied Move

±10.01%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations and raises guidance, history suggests the stock could rise by an average of 1.27% on the day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement, reflecting cautious investor sentiment.

Miss

Should CRL miss expectations, history indicates a potential decline of around 8.50% based on past reactions.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on revenue growth from life sciences services.
2Insights into cost management strategies in the current economic climate.
3Details on new service offerings and their expected impact on growth.
4Management's outlook on the competitive landscape in the biotech sector.
5Any commentary on the impact of macroeconomic factors on future performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the Health Care sector, focusing on life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well CRL is managing its costs and generating income.

Expected to be around $2.06.

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand its market share and support future investments.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

Management Promises & Guidance

Management emphasized a commitment to maintaining strong operational efficiency.
They indicated ongoing investments in research and development to drive future growth.
Management also highlighted the importance of expanding their service offerings in the biotech sector.

Expectations

Wall Street Expectations

Bull Case

If CRL can demonstrate strong revenue growth and maintain or improve its margins, it could lead to significant stock appreciation, especially given its history of beating EPS estimates.

Bear Case

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.06.

EPS is a key indicator of profitability and will show how well CRL is managing its costs and generating income.

Revenue Growth

Not available.

Revenue growth is vital for assessing the company's ability to expand its market share and support future investments.

Operating Margin

Not available.

Operating margin will help investors understand how efficiently CRL is operating relative to its revenue.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can CRL provide for its life sciences services?

Given the importance of revenue growth in the current market environment, clear figures will help investors gauge the company's future trajectory.

How is CRL managing its operational costs amidst rising inflation?

Understanding cost management strategies will be crucial for assessing the company's profitability and operational efficiency moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CRL's ability to leverage its recent investments in R&D, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

CRL has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.

Recent trends in the biotech sector show increased demand for CRL's services, which could drive revenue higher.

Key Risk

If CRL's revenue growth comes in below 5%, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around CRL's ability to sustain growth in a competitive market while managing costs effectively.

Bull Confirmed If

Demonstrating revenue growth of at least 10% year-over-year would confirm a strong bull case.

Bear Confirmed If

If revenue growth is flat or negative, it would raise significant concerns about CRL's market position.

Pre-Earnings Positioning

Options Market

Implied Move

±10.01%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations and raises guidance, history suggests the stock could rise by an average of 1.27% on the day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement, reflecting cautious investor sentiment.

Miss

Should CRL miss expectations, history indicates a potential decline of around 8.50% based on past reactions.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on revenue growth from life sciences services.
2Insights into cost management strategies in the current economic climate.
3Details on new service offerings and their expected impact on growth.
4Management's outlook on the competitive landscape in the biotech sector.
5Any commentary on the impact of macroeconomic factors on future performance.